MD Anderson at the 2024 AACR Annual Meeting

MDAnderson.org/AACR

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

All times are listed in Pacific Time. As of April 1.

Saturday, April 6		
8-9:30 a.m.	ED01 - Data Science Opportunities and Challenges in Biomarker-Based Early Detection of Cancer ⏐ Ballroom 6 CF - Upper Level - Convention Center	
8:01-8:21 a.m.	Features and data	Paul Scheet, Ph.D.
8-9:30 a.m.	ED21 - A Decade of Cancer Vaccines: Dedicated to the Memory of Harald zur Hausen ⏐ Ballroom 20 CD - Upper Level - Convention Center	
8:30-8:50 a.m.	Neoantigen vaccines for cancer interception in high-risk populations	Eduardo Vilar-Sanchez, M.D., Ph.D.
2:30-4 p.m.	MW12 - Functional Variomics and Network Approaches in Cancer Research ⏐ Room 28 - Upper Level - Convention Center	
2:30-2:50 p.m.	Functional variomics accelerates cancer research through big data-driven AI approach	Nidhi Sahni, Ph.D.
2:30-4 p.m.	ED17 - How Do Epigenetic Modifiers Shape Immune Responses Against Cancer? ⏐ Ballroom 6 CF - Upper Level - Convention Center	
3-3:30 p.m.	Leveraging epigenetics for rational immunotherapy combination	Rugang Zhang, Ph.D.
Sunday, April 7		
1-2:30 p.m.	SY31 - Neuronal Signaling, Unlocking a New Hallmark of Cancer ⏐ Room 5 - Upper Level - Convention Center	
1-1:05 p.m.	Introduction	Moran Amit, M.D., Ph.D.
1:55-2:15 p.m.	SY31-03 - Cancer takes a nerve: Challenges and opportunities in cancer neuroscience	
1-2:30 p.m.	ADT08 - Oligometastasis: Curable Metastatic State? ⏐ Room 28 - Upper Level - Convention Center	
1:55-2:15 p.m.	Re-examining the paradigm for local therapy in oligo- and poly-metastatic lung cancer	John Heymach, M.D., Ph.D.
1-3 p.m.	CTPL01 - Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies ⏐ Hall GH - Ground Level - Convention Center	
1:30-1:45 p.m.	CT002 - CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the Phase I COBALT-RCC study	Samer Srour, M.B.Ch.B.
2-2:15 p.m.	CT003 - Initial results from an open-label Phase Ib/II study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)	Michael Migden, M.D.
1:30-5 p.m.	**Posters** ⏐ Halls A, C, and F **See the full listing of posters from MD Anderson starting on page 5.**	
3-4:45 p.m.	MS.MD01.01 - Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases ⏐ Room 5 - Upper Level - Convention Center	
3:20-3:35 p.m.	1250 - Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer	Saikat Chowdhury, Ph.D.
3-5 p.m.	CTMS01 - Cancer Vaccines: Ready for Prime Time? ⏐ Ballroom 20 AB - Upper Level - Convention Center	
3-3:05 p.m.	Co-chair/Introduction	Ecaterina Dumbrava, M.D.
3-5 p.m.	MS.IM01.03 - Tumor-Targeted Immune Cell Engagers ⏐ Room 30 - Upper Level - Convention Center	

Time	Session	Speaker
3-3:10 p.m.	Co-chair/Introduction	David Hong, M.D.
3-5 p.m.	MS.TB11.01 - Microbes and Tumors: Time for Mechanisms ⎪ Room 16 - Mezzanine Level - Convention Center	
3-3:05 p.m.	Co-chair/Introduction	Florencia McAllister, M.D.
4:20-4:35 p.m.	1283 - Digital spatial profiling of metastatic brain tumors reveals association of the tumor microbiome with immune alterations in the tumor microenvironment	Golnaz Morad, Ph.D.
3-5 p.m.	MS.ET01.01 - Biological Therapeutic Agents ⎪ Room 15 - Mezzanine Level - Convention Center	
3:20-3:35 p.m.	1215 - DIRAS3 inhibits oncogenic RAS signaling and RAS-dependent cell growth driven by prevalent KRAS hot spot mutations	Gamze Bildik, Ph.D.
3-5 p.m.	MS.MCB06.01 - Cancer Epigenetics ⎪ Ballroom 6 A - Upper Level - Convention Center	
3:35-3:50 p.m.	1244 - Exploiting the pathogenesis of endogenous retrovirus to tackle squamous cancers	Yejing Ge, Ph.D.
3-5 p.m.	MS.CL01.03 - Biomarkers Predictive of Therapeutic Benefit ⎪ Ballroom 6 CF - Upper Level - Convention Center	
4:20-4:35 p.m.	1212 - Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC	Marcelo Negrao, M.D.
3:30-5:30 p.m.	CTPL02 - Novel Immune Checkpoint Inhibitor Combinations ⎪ Hall GH - Ground Level - Convention Center	
4:15-4:25 p.m.	Discussant	Michael Overman, M.D.
4-5:30 p.m.	DC15 - Engaging Community Members to Prioritize Research and Improve Cancer Care ⎪ Room 1 - Upper Level - Convention Center	
5:05-5:20 p.m.	Implementation of a community-based multi-component cancer screening intervention supported by a cross-sector community coalition	Ruth Rechis, Ph.D.
4:30-5:15 p.m.	LE17 - AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research ⎪ Room 31 - Upper Level - Convention Center	
4:30-4:35 p.m.	Chair/Introduction	Andrew Futreal, Ph.D.
4:35-5:15 p.m	Adaptive Resistance in BRAF- and KRAS-mutated Colorectal Cancer	Scott Kopetz, M.D., Ph.D.
6-8 p.m.	TM06 - Artificial Intelligence for Research Enhancement in Population Sciences: A Population Sciences Working Group Town Hall Meeting ⎪ Sapphire Ballroom - Hilton Bayfront Hotel	
6:30-6:40 p.m.	AACR Population Sciences Working Group Overview	Paul Scheet, Ph.D.
Monday, April 8		
9 a.m.-12:30 p.m.	**Posters ⎪ Halls A, C, and F** **See the full listing of posters from MD Anderson starting on page 5.**	
10:15 - 11:45 a.m.	SY47 - Surgical Innovations in Breast Cancer ⎪ Room 11 - Upper Level - Convention Center	
10:45 - 11:05 a.m.	Transformational potential of selective elimination of breast cancer surgery among patients with exceptional responses to neoadjuvant systemic therapy	Henry Kuerer, M.D.
10:15 - 11:45 a.m.	SY38 - The Growing Impact of Obesity on Cancer and Cancer Immunotherapy Outcomes ⎪ Room 30 - Upper Level - Convention Center	
11:10-11:30 a.m.	Obesity and melanoma: The interplay of host and tumor metabolism	Jennifer McQuade, M.D.
10:15 a.m.-12:15 p.m.	CTPL03 - Advances in Targeted Therapy ⎪ Ballroom 20 AB - Upper Level - Convention Center	
11:10-11:15 a.m.	CT013 - KRYSTAL-1: Pooled Phase I/II efficacy and safety of adagrasib (MRTX849) in combination with cetuximab in patients with metastatic colorectal cancer (CRC) harboring a KRASG12C mutation	Scott Kopetz, M.D., Ph.D.
11:40-11:55 a.m.	CT014 - PETRA: first-in-human Phase I/IIa trial of the first-in-class new generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations	Timothy Yap, M.B.B.S., Ph.D.

10:15 a.m.-noon	SY01 - Presidential Select Symposium: Cancer Immunotherapy - Where Do We Go from Here?	Hall GH - Ground Level - Convention Center	
10:20-10:40 p.m.	Immune checkpoint blockade in cancer therapy: Historical perspective, new opportunities, and prospects for cures	James Allison, Ph.D.
12:30-2 p.m.	SY24 - Neoadjuvant Therapies	Ballroom 6 B - Upper Level - Convention Center	
12:30-12:35 p.m.	Chair/Introduction	Kelly Hunt, M.D.
12:35-12:55 p.m.	Neoadjuvant therapy in breast cancer: Endpoints, targets and future directions	
12:30-2 p.m.	AHM04 - Ongoing Advances in the Understanding and Treatment of Acute Myeloid Leukemia	Room 14 - Mezzanine Level - Convention Center	
12:35-12:50 p.m.	AML: Ongoing advances and increasingly individualized treatment options	Courtney DiNardo, M.D.
1:30-5 p.m.	**Posters**	**Halls A, C, and F** **See the full listing of posters from MD Anderson starting on page 5.**	
2:30-4:30 p.m.	MS.CL01.02 - Early Detection and Progression Biomarkers	Ballroom 6 B - Upper Level - Convention Center	
2:35-2:50 p.m.	3893 - A multimodal spatial-omics atlas of lung precancer and progression to adenocarcinoma	Ansam Sinjab, Ph.D.
2:30-4:30 p.m.	MS.PS01.02 - Cancer Disparities Research	Room 14 - Mezzanine Level - Convention Center	
2:35-2:50 p.m.	3942 - Mailed at-home self-sampling for HPV testing increases screening participation among under-screened patients in a U.S. safety net health system: Results of the PRESTIS trial	Trisha Amboree, Ph.D.
2:30-4:30 p.m.	CTMS02 - Advances in Immunotherapy	Hall GH - Ground Level - Convention Center	
2:50-3 p.m.	CT030 - Randomized placebo-controlled, biomarker-stratified Phase Ib microbiome modulation trial for metastatic melanoma demonstrates impact of antibiotic pre-conditioning regimen on the microbiome and immunity	Yongwoo David Seo, M.D.
2:30-4:30 p.m.	MS.IM02.01 - Understanding and Targeting Pathogenic Inflammation in Solid Tumors	Room 28 - Upper Level - Convention Center	
2:50-3:05 p.m.	3922 - Quaking modulates anti-tumor immunity by regulating antigen processing and presentation in dendritic cells	Yating Li
2:30-4:30 p.m.	MS.MCB08.01 - Advances in Cancer Genomics: Carcinogenesis, Tumor Evolution, and Heterogeneity	Room 31 - Upper Level - Convention Center	
3:05-3:20 p.m.	3930 - The therapeutic implications of consensus genomic subtypes of gastric adenocarcinoma	Yun Seong Jeong
3:00-3:45 p.m.	LE18 - AACR-Women in Cancer Research Charlotte Friend Lectureship	Room 17 - Mezzanine Level - Convention Center	
3:05-3:45 p.m.	Invited Speaker	Elizabeth Travis, Ph.D.
Tuesday, April 9		
9 a.m.-12:30 p.m.	**Posters**	**Halls A, C, and F** **See the full listing of posters from MD Anderson starting on page 5.**	
10:15-11:45 a.m.	ADT07 - Radiotheranostics: A Paradigm-Shifting Therapy	Room 11 - Upper Level - Convention Center	
10:40-11:05 a.m.	Priming anti-cancer immunity with radioligand therapy	David Piwnica-Worms, M.D., Ph.D.
10:15-11:45 a.m.	AHM02 - Immune Microenvironment in Hematologic Malignancies	Room 15 - Mezzanine Level - Convention Center	
10:45-11:05 a.m.	Immune dysfunction in myelodysplastic syndrome at disease initiation and progression	Simona Colla, Ph.D.
10:15-11:45 a.m.	SY17 - The Microbiome and Treatment Response to Cancer Therapy	Room 16 - Mezzanine Level - Convention Center	
10:45-11:05 a.m.	Microbiome and cancer treatment toxicities	Rob Jenq, M.D.

10:15-11:45 a.m.	SY08 - Health Behavior Practices after Cancer Diagnosis to Deter Cancer Progression and Death: Evidence, Gaps, and Solutions │ Ballroom 6 DE - Upper Level - Convention Center	
11-11:20 a.m.	Improving diet quality and increasing physical activity in cancer survivors: Successes, challenges, and next steps	Karen Basen-Engquist, Ph.D.
1:30-5 p.m.	**Posters │ Halls A, C, and F** **See the full listing of posters from MD Anderson starting on page 5.**	
2:30-4:30 p.m.	CTMS03 - Novel Agents and Emerging Therapeutic Strategies │ Hall GH - Ground Level - Convention Center	
2:30-2:45 p.m.	CT038 - Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase II study	Jordi Rodon, M.D., Ph.D.
2:50-3 p.m.	CT037 - A Phase I investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory B-cell non-Hodgkin lymphoma	Paolo Strati, M.D.
3:35-3:45 p.m.	CT042 - NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations	Timothy Yap, M.B.B.S., Ph.D.
2:30-4:30 p.m.	MS.CL06.01 - Immuno-oncology │ Ballroom 20 CD - Upper Level - Convention Center	
2:30-2:35 p.m.	Chair/Introduction	Cassian Yee, M.D.
2:30-4:30 p.m.	MS.TB05.01 - Nonclinical Models of Cancer │ Room 33 - Upper Level - Convention Center	
2:31-2:32 p.m.	Chair	Helen Piwnica-Worms, Ph.D.
2:35-2:50 p.m.	6620 - PDX models of TNBC established from pre- and post-therapy tumors identify vulnerabilities of resistant disease	Amanda Rinkenbaugh, Ph.D.
2:30-4:30 p.m.	MS.IM01.01 - New Insights for Therapies Modulating Antitumor T-Cell Responses │ Ballroom 6 B - Upper Level - Convention Center	
2:31-2:32 p.m.	Chair	Michael Curran, Ph.D.
4:20-4:30 p.m.	Closing remarks	
6-8 p.m.	TM01 - Is Cancer Evolution Key to Understanding and Strategically Applying the Multiple Cancer Early Detection (MCED) Assays?: A Cancer Evolution Working Group Town Hall Meeting │ Sapphire Ballroom - Hilton Bayfront Hotel	
7:10-7:20 p.m.	Invited Speaker	Nicholas Navin
Wednesday, April 10		
9 a.m.-12:30 p.m.	**Posters │ Halls A, C, and F** **See the full listing of posters from MD Anderson starting on page 5.**	
10:15-11:15 a.m.	NIH12 - NCI Artificial Intelligence Programs and Resources for Advancing Cancer Research │ Room 2 - Upper Level - Convention Center	
10:43-10:55 a.m.	Towards a learning, sharing community to support safe and effective AI research in oncology	Christopher Gibbons, Ph.D.
10:15-11:45 a.m.	SY18 - Tumor Microbiome │ Room 28 - Upper Level - Convention Center	
11:15-11:25 a.m.	Function of tumor resident microbes	Florencia McAllister, M.D.
10:15-11:45 a.m.	SY45 - Engineering Strategies Based on NK, and gd T Cells and Their Receptors, and Macrophage │ Ballroom 6 A - Upper Level - Convention Center	
10:20-10:40 a.m.	Advancing cancer immunotherapy: The emerging role of engineered NK cells	Katy Rezvani, M.D., Ph.D.
On-Demand	MS.ET03.01 - Conquering Drug Resistance by Innovative Research	
	Co-chair/Introduction	Dihua Yu, M.D., Ph.D.

Posters

Sunday, April 7

1:30-5 p.m.	Posters	Halls A, C, and F	

LBPO.IM01 - Late-Breaking Research: Immunology 1 | Section 54

LB079 / 15 - Cell-specific deletion of Bhlhe40 reveals distinct mechanisms underlying anti-PD-1 and anti-CTLA-4	A. Saha

PO.BCS01.01 - Application of Bioinformatics to Cancer Biology 1 | Section 47

863 / 7 - Scratch: A highly modular pipeline for single-cell cancer research	A. Fonseca
873 / 17 - Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA profiles	S. He
881 / 25 - Cell-type-specific gene programs suggest immune and stromal drivers of relapse in colorectal cancer	N. Hornstein

PO.CL01.05 - Spatial Proteomics and Transcriptomics | Section 46

1146 / 13 - Pan-cancer characterization of cancer cell state and plasticity using spatially resolved transcriptomics	G. Pei
1148 / 15 - Multimodal spatial transcriptomics and proteomics analysis of the resectable NSCLC ecosystem following neoadjuvant chemoimmunotherapy	Z. Rahal
1152 / 19 - Pan-cancer single-cell and subcellular characterization of lymphoid aggregates and tertiary lymphoid structures using high-plex spatial molecular imaging	Y. Liu

PO.CL05.01 - Clinical Research in Special Populations | Section 41

7454 / 29 - Cognitive function in older breast cancer survivors after chemotherapy	R. Kim

PO.CL06.05 - Tumor Immune Response 1 | Section 47

1168 / 2 - Anti-CSF1R antibody monotherapy inhibits minimal residual disease in a novel immunocompetent murine colorectal cancer metastasis model	A.M.T. Mohamed
1179 / 13 - A single-cell atlas of human gastric malignancy reveals CD8+ T cell rejuvenation as a mediator of immunotherapeutic response	H. Liang

PO.CL07.01 - Pediatric Sarcomas and Other Solid Tumors: Translational | Section 44

1083 / 4 - Cell membrane-anchored and tumor-targeted IL12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models	J. Hu
1084 / 5 - Preclinical testing of a cell adhesion molecule 1 (CADM1) targeting antibody-drug conjugate in osteosarcoma and other pediatric solid tumor models	Z. Zhang

PO.CL08.03 - Application of Precision Medicine for Cancer Care | Section 39

39 / 7 - Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors	B. Uzunparmak

PO.CL09.01 - Radiation Oncology | Section 45

8 / 12 - Mitigating radiation-induced lymphopenia using interleukin-15: Preclinical rationale for clinical translation	P. Gupta

PO.ET02.06 - Tumor Microenvironment | Section 29

725 / 11 - Listeria-inspired phagosome escape drives STING responses to CD47 blockade	B. R. Schrank

PO.ET05.01 - Cell Cycle, Transcription Regulation, and Anticancer Drug Action | Section 21

518 / 15 - The CDK2/9 inhibitor fadraciclib is active in Richter transformation and lymphoma cell lines by targeting both cell survival and proliferation	R. Chen
522 / 19 - TP53 mutations promote death of breast cancer cells following Kif11 inhibition	A. L. Lanier

PO.ET08.01 - Radiotherapeutic Combinations, Modifiers, Protectors, Sensitizers, and Molecular Targets | Section 28

692 / 5 - Uncoupling protein 2 (Ucp2) loss of function enhances mitochondrial ROS and sensitizes PDAC to radiation therapy	E. G. Caggiano
693 / 6 - The effect of butyrophilin 1A1 blockade in combination with radiation treatment in tumor models	N. Li
697 / 10 - Enhanced tumor control and survival in solid tumor models following combined low dose radiotherapy and T cell therapy	N. Puebla

PO.ET09.05 - Novel Antitumor Agents 2 | Section 27

676 / 22 - The integrated stress activator BTM-3566 overcomes therapeutic resistance in mantle cell lymphoma	Y. Liu

PO.ET09.13 - Kinase and Phosphatase Inhibitors 1 | Section 25

602 / 12 - Targeting CDK9 with a novel potent and selective inhibitor, YX0798, in CAR-T-relapsed mantle cell lymphoma models	V. Jiang
PO.IM01.13 - Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T │ Section 1	
24 / 24 - Utilizing T cell receptor-based therapy to treat anaplastic thyroid cancer	S. H. Hung
PO.IM01.14 - Adoptive Cell Therapies 2: CAR-T Cells │ Section 2	
33 / 1 - Revitalizing CAR-T cells for TNBC: Targeting phosphorylation of TCF7 to overcome T cell exhaustion	Z. Jiang
44 / 12 - A novel, codon-based method to modulate off-tumor toxicity of chimeric antigen receptor (CAR) T cells	R. A. Vedia
PO.MCB09.01 - Metabolic Pathways 1 │ Section 18	
446 / 24 - Integrated spatial transcriptomics and lipidomics analyses of intraductal papillary mucinous neoplasm identifies enrichment of long chain sulfatide as an early metabolic alteration	Y. Chen
PO.PR01.03 – Epidemiology │ Section 32	
778 14 - Atorvastatin modulates serum biomarkers in women at increased risk for breast cancer	A. L. Lanier
780 / 16 - Normal breast tissues harbor rare populations of aneuploid epithelial cells	Y. Lin
PO.PS01.02 - Cancer Disparities 1: Emerging Trends in Cancer Disparities Research │ Section 33	
816 / 21 - Implementation of a community-based multi-component cancer screening intervention supported by a cross-sector community coalition	R. Rechis
PO.TB04.04 - Membrane, Biophysical, and EMT Aspects of Motility/Metastasis │ Section 8	
206 / 15 - Intratumoral accumulation of CD38 enhances immune evasion and metastasis in models of breast cancer with EMT plasticity	T. Visal
PO.TB06.01 - Developmental Origins and Drivers of Pediatric Cancer │ Section 6	
129 / 1 - Understanding the molecular drivers that regulate Ewing sarcoma cell fate	D. Truong
130 / 2 - Multi-omic analysis of desmoplastic small sound cell tumors reveal distinct epithelial and neuroendocrine lineages	D. Truong
139 / 11 - Modeling and genomic profiling of osteosarcoma development in murine chondrocyte-origin models	X. Zhou
148 / 20 - Multiomic sequencing reveals diversity in clonal landscape and genomic alterations in a lung metastatic PDX osteosarcoma model	S. Jusu
PO.TB08.01 - Stem Cells in Tumor Initiation and Progression │ Section 10	
257 / 10 - Plasticity of preneoplastic cells drives esophageal squamous cell cancer initiation	K. Ko
PO.TB09.01 - Tumor Adhesion │ Section 12	
307 / 5 - Generation and characterization of a glioblastoma stem cell model with acquired resistance to LSD1 inhibition	K. H. Patel
PO.TB11.05 - Stroma Interactions │ Section 11	
270 / 1 - Dissecting the effects of p53 mutation and p53 loss on pancreatic tumor microenvironment	Y. Chen
Monday, April 8	
9 a.m.-12:30 p.m. │ **Posters** │ **Halls A, C, and F**	
LBPO.CL01 - Late-Breaking Research: Clinical Research 1 │ Section 51	
LB090 / 1 - Predictive genomic biomarkers for atezolizumab plus bevacizumab combination immunotherapy response in liver cancer: Insights from the IMbrave150 trial	J. S. Lee
LBPO.IM02 - Late-Breaking Research: Immunology 2 │ Section 52	
LB121 / 9 - Endothelial cells mediated paracrine signaling alters immune cell modulators on colorectal cancer cells	R. Bhattacharya
LBPO.PS01 - Late-Breaking Research: Population Sciences │ Section 53	
LB143 / 10 - Environmental assessment of alcohol-related policies and practices at U.S. cancer organizations	M. Si
PO.BCS01.12 - New Algorithms, Software, and Models │ Section 37	
2332 / 10 - Enhanced analysis of CO-Detection by indEXing (CODEX) imaging through a novel image processing technique utilizing two-dimensional Fourier transform for stitching artifact detection	A. Jahedi
PO.CH02.01 - Proteomics and Mass Spectrometry 1 │ Section 21	
1845 / 8 - 11,000-plex aptamer based proteomics of colorectal cancer stools for the discovery of novel disease biomarkers	C. Mohan
PO.CL01.07 - Predictive Biomarkers 1 │ Section 43	
2501 / 18 - High mutation burden and ultraviolet light signature in conjunctival squamous cell carcinoma	B. Esmaeli

PO.CL02.01 - Biostatistics in Clinical Trials / Surgical Oncology	Section 39	
2396 / 11 - Tumor treating fields (TTFields) for spinal metastasis: Clinical trial concept for use of conductive implants as waveguides to enhance TTFields strength	C. E. Tatsui
PO.CL10.01 - Real-World Biomarkers Section 45	
2547 / 7 - KRAS Q61 mutations in patients with gastrointestinal malignancies and association with real-world clinical outcomes	M. Yousef
PO.CT01.04. Phase I Clinical Trials 1 Section 48	
CT060 / 10 - Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)	G. Garcia-Manero
CT066 / 16 - Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53	E. Dumbrava
PO.CTP01.01 - Phase I Clinical Trials in Progress 1 Section 49	
CT075 / 2 - A Phase 1 trial evaluating AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer	R. M. Layman
CT077 / 4 - An open-label Phase I study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)	F. Meric-Bernstam
CT081 / 8 - A Phase I/II study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors	E. Dumbrava
PO.ET03.04 - Drug Resistance 2: Ras GTPase Section 24	
1929 / 7 - Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition and regulated by 4E-BP1	I. M. Meraz
1935 / 13 - The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance	Y. Shibata
1937 / 15 - YAP-TAZ-TEAD transcriptional program is a prominent driver of acquired resistance to KRASG12C-based therapies in patients with metastatic colorectal cancer	O. Coker
1940 / 18 - Identifying resistant mechanisms to direct KRAS inhibitors in NSCLC	S. T. Kundu
PO.ET09.07 - Kinase and Phosphatase Inhibitors 2 Section 24	
1958 / 7 - EGFR and mTOR signaling facilitate RET-independent resistance to selective RET-TKIs	T. Takehara
1964 / 13 - Furmonertinib is a brain-penetrant EGFR TKI highly active in uncommon EGFR mutations, including PACC and exon 20 insertions	X. Le
PO.MCB08.02 - Genomic Characterization of Cancers and Cancer Subgroups Section 17	
1749 / 4 - Esophageal adenocarcinoma single-cell resolution ecotypes and subtypes mediate chemoradiation resistance	R. Ye
1754 / 9 - Test-the-test: Clinical utility of comprehensive whole exome sequencing (WES) and RNA-seq for lymphoma patients	D. Chihara
1758 / 13 - Chromosome 3 copy number loss alone drives tumor evolution to aggressive disease in uveal melanoma	S. Srinivasan
1765 / 20 - The genetic landscape of head and neck cancer using brush biopsy	E. John
1768 / 23 - Investigating oncogene amplifications in brain metastasis of esophageal adenocarcinoma samples	N. Lawson
PO.MCB09.02 - Metabolic Pathways 2 Section 18	
1803 / 25 - ACOD1 is a key regulator of immunosuppressive MDSCs, prostate cancer progression, and resistance to immunotherapy	G. Wang
2152 / 19 - Evaluating beliefs and perceived competence about tobacco cancer prevention practices in Texas local mental health authorities	A. D. Siddiqi
PO.PR02.01 - Role of Diet, Nutrition, and the Microbiome Across the Cancer Continuum Section 32	
2176 / 10 - Differences in gut microbial composition alter pancreatic tumorigenesis	R. M. Howell
2182 / 16 - 15-lipoxygenase-1 modulation of colonic resolvin production to suppress colorectal carcinogenesis	X. Zuo
PO.TB04.05 - Contributors to Metastatic Organotropism Section 8	
1494 / 7 - Clonal dominance defines metastatic dissemination in pancreatic cancer	I. L. Ho
1502 / 15 - Deciphering the spatial and temporal dynamics of premetastatic niche in lung mediated by Treg and myeloid cell interactions	Y. Tian
PO.TB05.01 - Animal Models of Cancer Section 6	

1447 / 18 - Development of advanced preclinical modeling for a comprehensive characterization of cardiac angiosarcoma biology	R. Minelli

PO.TB10.02 - Tumor Evolution in Space and Time ⎪ Section 12

1612 / 4 - Timing ecDNA acquisition across cancer	A. R. Lynch
1613 / 5 - Evolution of mutations in the antigen presentation machinery across cancers	S. S. Gu

PO.IM01.02 - Immune Checkpoints and Inhibitory Molecules 1 ⎪ Section 3

1354 / 5 - Anti-CTLA-4 generates memory T-cells with greater expansion and functionality than anti-PD-1	S. Mok

PO.IM01.05 - Inflammation, Host Factors, and Epigenetic Influences on Cancer Development and Treatment ⎪ Section 5

1420 / 18 - Mechanism of NPRL2 gene therapy induced antitumor immunity in KRAS/STK11mt aPD1 resistant metastatic NSCLC	I. M. Meraz

PO.TB11.07 - Immune Cells in the Tumor Microenvironment 1 ⎪ Section 9

6869 / 11 - Paired single-cell B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cell immunity in acute myeloid leukemia	G. S. Mohan

1:30-5 p.m. ⎪ Posters ⎪ Halls A, C, and F

LBPO.ET02 - Late-Breaking Research: Experimental and Molecular Therapeutics 2 ⎪ Section 52

LB158 / 4 - Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: implications for novel therapy	A. M. Tsimberidou
LB162 / 8 - Tinengotinib in patients with advanced solid tumors harboring actionable FGFR1-3 mutations	S. Piha-Paul
LB180 / 26 - Non-cardiotoxic properties of annamycin, a clinically evaluated anthracycline and potent topoisomerase 2β poison	R. J. Zielinski

LBPO.MCB01 - Late-Breaking Research: Molecular/Cellular Biology and Genetics 1 ⎪ Section 53

LB188 / 4 - PEA-15 phosphorylation mediates pro-tumor effects by promoting β-catenin activity in TNBC	A. W. Tan

PO.BCS01.03 - Application of Bioinformatics to Cancer Biology 3 ⎪ Section 34

3501 / 23 - Concurrent amplification of TBXT and highly activated enhancers in extrachromosomal DNA (ecDNA) drives chordoma tumorigenesis	B. Zhao

PO.BCS01.09 - Database Resources, Statistical Methods, and Other Tools ⎪ Section 36

3564 / 24 - Survival-based grouping of genetic variants: A novel statistical framework with an application to TP53 mutations	X. Liu

PO.CL01.06 - Biomarkers in Clinical Trials ⎪ Section 40

3646 / 24 - A spatially resolved single cell proteomic atlas of small bowel adenocarcinoma	Z. Dereli

PO.CL01.14 - Diagnostic Biomarkers 2 ⎪ Section 44

3765 / 21 - Single cell spatial proteomics analysis and computational evaluation pipeline	Behnaz Bozorgui

PO.CL06.01 - Adoptive Cellular Therapy 1 ⎪ Section 39

3605 / 11 - Phase II study of pembrolizumab in conjunction with lymphodepletion, TIL ACT, and high- or low-dose IL-2 in patients with metastatic melanoma	S. Kiany

PO.CL06.04 - Tumor Immune Response 2 ⎪ Section 47

3847 / 8 - Dual targeting of EGFL6 and VEGF-A to overcome immune suppression in ovarian cancer	S. Umamaheswaran
3853 / 14 - T cell ferroptosis attenuates antitumor immune responses in sickle cell disease	Z. Zhao
3858 / 19 - Peripheral CD38+ effector memory (EM) T cells are dynamic biomarkers of response to neoadjuvant immune checkpoint blockade (NeoICB) in patients (pts) with resectable dedifferentiated liposarcoma (DDLPS) and undifferentiated pleomorphic sarcoma (UPS)	E. Z. Keung

PO.CL06.12 - Combination Immunotherapies ⎪ Section 43

3724 / 10 - Targeting the LIFR-LCN2 pathway to sensitize liver cancer to immunotherapy	Y. Deng
3725 / 11 - Exosomal Galactin-3 promotes pre-metastatic niche formation that accelerates peritoneal metastases of gastric adenocarcinoma	Y. Fan

PO.CL10.04 - Outcome Investigation with Real World Data ⎪ Section 46

3815 / 5 - Clinical efficacy and safety of HER2 targeted therapy in patients with metastatic colorectal cancer: A systematic review and meta-analysis	O. E. Villarreal

PO.CT01.03. Phase 0 and Phase I Clinical Trials ⎪ Section 49

CT138 / 17 - Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort	A. M. Tsimberidou
CT144 / 23 - Safety and efficacy of HMPL-523 (Syk inhibitor) in patients with relapsed or refractory lymphoma	P. Strati

PO.CTP01.02 - Phase I Clinical Trials in Progress 2 │ Section 50	
CT152 / 3 - FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations	X. Le
CT169 / 20 - First-in-human, Phase I/II study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors	T. Yap
PO.EN01.01 - Molecular, Preclinical, and Clinical Endocrinology 1 │ Section 38	
3574 / 3 - Cancer testis antigen expression correlates with stromal natural killer cell activation and longer overall survival in small bowel neuroendocrine tumors	R. I. Ayabe
3590 / 19 - Tumor intrinsic production of glucocorticoids in ovarian carcinoma	P. Hanjra
PO.ET01.03 - Cancer Biology and Metastasis │ Section 22	
3161 / 9 - PCTK1 driven glutamine metabolic adaptation in brain metastasis	L. Zhang
PO.ET03.02 - Mechanisms of Drug Resistance 2 │ Section 26	
3280 / 20 - ASCL2+ tumor cells modulate the response of colorectal cancer to MAPK targeting therapy	O. E. Villarreal
PO.ET06.03 - Novel Therapeutics │ Section 29	
3344 / 1 - Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA binding proteins	B. Kaundal
3351 / 8 - Identifying novel therapies from unbiased screens in AML with MECOM re-arrangement	C. E. Birdwell
3371 / 28 - PRMT blockade induces defective DNA replication stress response via ATR suppression and synergizes with PARP inhibition	D. Bisht
PO.ET09.02 - Epigenetic Targets │ Section 24	
3229 / 13 - IACS-16559, a CBP/P300 bromodomain inhibitor for the treatment of specific AML subsets	Ciro Zanca
3241 / 25 - Elevated H3K27 trimethylation mediates adaptation to DNA demethylation in BRAFV600E-mutated colorectal cancer	H. Lee
PO.ET09.04 - Molecular Glues │ Section 27	
3304 / 11 - Modulation of enhancer accessibility by SMARCA2 PROTACs synergize with TEAD inhibitors to suppress growth of SMARCA4 mutant lung cancers	Y. Lissanu
PO.ET09.08 - Novel Antitumor Agents 3 │ Section 28	
3321 / 9 - KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models	D. H. Peng
PO.IM01.03 - Immune Checkpoints and Inhibitory Molecules 2 │ Section 4	
2667 / 21 - Mucin 5AC inhibition via intratracheal RNAi delivery as an effective alternative strategy for prevention and treatment of Kras mutant lung cancer	M. Zarghooni
2672 / 26 - GD3 synthase (ST8SIA1) is a key immunomodulator in GD2+ breast cancer cells	B. Oderinde
PO.IM01.16 - Antibody-Drug Conjugates │ Section 2	
2603 / 6 - Targeting chemo-resistant ovarian cancer with a first-in-class, first-in-human immune-oncology agents containing granzyme B	A. Alvarez-Cienfuegos
2606 / 9 - Targeting mesothelin on tumor cells with a novel, completely human fusion construct delivering the serine protease granzyme B	K. A. Mohamedali
PO.IM02.05 - Innate Immunity in Cancer │ Section 5	
2702 / 24 - Hyperprogression due to myeloid mimicry in renal medullary carcinoma treated with nivolumab plus ipilimumab	X. Yan
PO.MCB07.01 - Oncogenic Transcription Factors │ Section 18	
3038 / 8 - PPARδ promotes gastric adenocarcinoma carcinogenesis by enhancing ZBP1-induced necroptosis and inflammation and fostering gastric tumor immunosuppressive microenvironment	Y. Liu
3044 / 14 - Novel agents with efficacy against germline mutant RUNX1 familial platelet disorder with myeloid malignancy (FPD-MM)	C. P. Mill
PO.MCB11.01 - New Insights into Tumor Suppressor Genes │ Section 17	
3009 / 7 - ATRX loss blocks the differentiation of mesenchymal stem cells and promotes undifferentiated sarcoma development	Y. Cai
PO.PR01.02 - Cancer Control and Survivorship │ Section 31	
3400 / 2 - Single-cell proteogenomics analysis of AML samples treated with decitabine and venetoclax reveals divergent treatment escape mechanisms	Y. Kim
PO.PR02.03 - Animal and Cellular Models of Cancer Prevention and the Study of Biological/Biochemical Mechanisms │ Section 30	

3379 / 3 - Single-cell profiling reveals dynamic epithelial and immune cell interactions in the progression of lung adenocarcinoma	H. Chen
3385 / 9 - Modeling evolutionary fitness in resistant cancers based on a common adaptability trait	B. Singh
3387 / 11 - Spatial analysis revealed distinct molecular and immune landscape in genetic versus carcinogen-induced lung adenocarcinoma precancer mouse models	B. Zhu

PO.TB04.02 - Biomarkers and Expression Differences in Metastatic Progression ⎪ Section 7

2756 / 14 - Single cell analysis reveals treatment response-associated plastic cell state and lineage switching in aggressive variant prostate cancer	Shuai Guo
2761 / 19 - Activating RET mutations promotes osteoblastic bone metastasis by inhibiting osteoclastogenesis and stimulating osteoblast activity via regulation of osteoprotegerin	R. Bagheri-Yarmand

PO.TB05.02 - Modeling Cancer in Mice ⎪ Section 10

2830 / 17 - Intravital multiphoton microscopy of bone metastatic renal cell carcinoma	S. Maksimovic

PO.TB06.02 - Pediatric Cancer Genomics and Epigenomics ⎪ Section 11

2851 / 7 - Characterization of neogenes in desmoplastic small round cell tumors	D. Truong
2864 / 20 - Transcriptional repressor REST controls autophagy in Sonic Hedgehog medulloblastoma through the VHL-HIF1α axis.	A. Singh

PO.TB07.01 - Radiation Science ⎪ Section 12

2885 / 16 - O-carborane-entrapped polymeric Micelles for Proton Boron Capture Therapy	Q.X. Teng

PO.TB08.02 - Cancer Stem Cells and Their Microenvironment ⎪ Section 8

2777 / 2 - A unique sub-population of PDGFRB+ glioma-associated mesenchymal stem cells constitute the perivascular niche in murine glioblastoma	M. F. Zaman

PO.TB11.10 - Microbiome and Cancer ⎪ Section 9

2801 / 8 - Identifying gut microbial determinants of clonal hematopoiesis of indeterminate potential (CHIP) in immunotherapy treated melanoma patients.	E. A. Fallon
2806 / 13 - A single dose of perioperative cefazolin disrupts the gut microbiome and immunity in patients (pts) with early-stage melanoma	E. Fernandez

Tuesday, April 9

9 a.m.-12:30 p.m.   Posters ⎪ Halls A, C, and F

LBPO.BCS02 - Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2 ⎪ Section 51

LB247 / 8 - TCPAplus: An LLM-empowered chatbot for analyzing a large protein expression atlas of human cancers	W. Liu

PO.BCS01.08 - Artificial Intelligence and Machine/Deep Learning 3   ⎪ Section 36

4931 / 27 - The Cancer Proteome Atlas: Expanded datasets and empowered with an AI-driven chatbot	H. Liang

PO.BCS01.10 - Integrative Computational Approaches 1 / Analytic Pipeline Optimization ⎪ Section 37

4946 / 11 - ssTimiGP: Equip the TimiGP system with a single-sample module, facilitating the cell-cell interaction inference of the tumor microenvironment in any sample	C. Li

PO.CL01.09 - Predictive Biomarkers 3 ⎪ Section 44

5141 / 14 - Autoantibody profiling for predictive biomarkers for immune-related adverse events and clinical benefit in rare tumors treated with anti-PD-1 therapy	M. H. Derbala

PO.CL01.11 - Predictive Biomarkers 4 ⎪ Section 45

5162 / 3 - Tumor transcriptional identity as a key predictor of clinical outcome in EGFR-Mutant non-small cell lung cancer	S. Heeke

PO.CL06.06 - Chemotherapy, Radiation, and Vaccine Mediated Immunity ⎪ Section 39

4986 / 3 - Single-cell multimodal characterization of ovarian cancer microenvironment under neoadjuvant niraparib treatment informs an effective therapeutic strategy of suppressing HRD-dependent eTreg hyper-expansion	Y. Luo

PO.CL13.01 - Molecular Biology in Clinical Oncology: Genetics and Beyond ⎪ Section 41

5053 / 7 - Clinicopathologic and molecular genetic features of STAT3-mutated myeloid neoplasms	M. T. Ye
5061 / 15 - Improved survival and unique mutational signatures in small cell lung cancer arising in patients with limited tobacco use	K. Concannon
5070 / 24 - Landscape of clonal hematopoiesis prior to PARP inhibitor treatment in patients with ovarian cancer	A. Asare

PO.ET01.04 - Mechanisms of Drug Resistance and Novel Combinations ⎪ Section 25

4622 / 20 - Anti-tumor activity of CDK2 inhibitor BLU-222 in combination with CDK4/6 inhibitors for overcoming resistance in HR positive and triple negative metastatic breast cancers models	L. Luo
PO.ET02.04 - Drug Combinations ⏐ Section 23	
4551 / 6 - A novel MET antibody drug conjugate-based combination therapy to overcome colorectal cancer plasticity and drug resistance	S. Subramanian
4552 / 7 - EGFR inhibitors increase LGR5 expression and enhance potency of LGR5 antibody-drug conjugates targeting colorectal cancer stem cells	P. C. High
4575 / 30 - FGFR3 altered bladder cancer exhibits a lineage-dependent vulnerability	M. Koleilat
PO.ET02.10 - New Targets, Technologies, and Drug Delivery Systems ⏐ Section 28	
4693 / 13 - A Phase 1b study of BYL719 (Alpelisib) in combination with androgen receptor inhibitor (enzalutamide) in patients with androgen receptor (AR)-positive and PTEN-positive metastatic breast cancer	M. Karuturi
PO.ET03.05 - Reversal of Drug Resistance 1 ⏐ Section 30	
4742 / 8 - Targeting the RNA-binding protein LARP1 overcomes therapeutic resistance in ovarian cancer	C. Rodriguez-Aguayo
PO.ET03.08 - New Compounds and Drug Targets ⏐ Section 27	
4652 / 5 - Combined inhibition of MCL-1 and MEK reduces tumor growth in a triple-negative/inflammatory breast cancer, MEK-resistant xenograft mouse model	M. Mughees
4654 / 7 - Targeting poly-resistant stem cells in high-grade serous ovarian cancer via synthetic lethal drugs	W. Xian
PO.ET09.01 - DNA Reactive Agents ⏐ Section 22	
4536 / 12 - MTAP loss alters the epigenetic landscape and demonstrates superior therapeutic sensitivity to concomitant PRMT5 and PARP inhibition in cholangiocarcinoma	P. A. Shah
PO.IM01.04 - Combination Approaches ⏐ Section 3	
4048 / 24 - Comparative effects of SOS1 inhibitor with IL-6 blockade and their combination on Kras mutant lung cancer	K. E. Larsen
PO.IM01.08 - Vaccines, Antigens, and Antigen Presentation 1 ⏐ Section 5	
4098 / 9 - A citrullinated-ENO1 peptide vaccine delayed tumor growth and markedly improved overall survival in a mouse model of triple-negative breast cancer	R. A. Leon Letelier
PO.IM01.15 - Adoptive Cell Therapies 3: CAR-T Cells ⏐ Section 2	
4005 / 14 - HER2 TKIs enhance the anti-tumor activity of HER2-targeting CAR-T and CAR-NK cells against NSCLC	Y. Yang
PO.IM02.01 - Adaptive Immunity in Tumors ⏐ Section 1	
3974 / 16 - Macronutrient composition dictates MASH-associated HCC immunosurveillance through microbiota alteration and metabolic adaptation	S. Shalapour
PO.MCB08.03 - Characterization of Mutational Processes and Drivers in Cancer Development and Evolution ⏐ Section 15	
4332 / 2 - Isoform-level transcriptome-wide analyses identify extensive genetic mechanisms for breast cancer risk undetectable on the gene-level	A. Bhattacharya
4338 / 8 - A pan-cancer single-cell analysis of intratumoral copy number diversity and evolution	H. Ye
PO.MCB09.05 - Signaling Pathways That Regulate Metabolism 2 ⏐ Section 19	
4450 / 4 - MYC upregulates MCT4 expression and promotes metabolic reprogramming and enhanced lactate utilization in LKB1-deficient NSCLC	Y. Qian
PO.PR02.04 - Biomarkers and Molecular Targets for Cancer Prevention ⏐ Section 31	
4779 / 15 - The effects of glutamine deprivation on ovarian cancer initiation and progression	S. Ferri-Borgogno
PO.PS01.08 - Descriptive Epidemiology and Statistical and Epidemiological Methodology ⏐ Section 34	
4849 / 6 - Mosaic chromosomal alterations in a prospective cohort of Mexican Americans for cancer risk and genetic insights	J. Valdebenito
4852 / 9 - High brain relapse rates in stage III triple negative inflammatory breast cancer are independent of systemic therapy	A. Nasrazadani
PO.TB03.01 - In Vivo Imaging and Anatomical and Molecular Pathology ⏐ Section 8	
4157 / 12 - Combining hyperpolarized magnetic resonance and positron emission tomography to interrogate prostate cancer metabolism	M. Wang
4166 / 21 - TSPO-targeted near-infrared optical probe for early identification and localization of high-risk premalignant pancreatic lesions	S. Sharma

4172 / 27 - Pathology supervised approaches for ROI placement and segmentation to overcome caveats and pitfalls in high-plex spatial profiling	S. Hernandez
PO.TB04.03 - Detection, Treatment, and Prevention of Metastasis ⏐ Section 7	
4128 / 10 - Biofield therapy suppressed invasion and metastases of human pancreatic cancer	P. Yang
4134 / 16 - The abscopal effect of combination IRE with αPD-1 treatment against PDACs	Q. Cao
PO.TB10.03 - Tumor Evolution Models and Technologies ⏐ Section 13	
4304 / 14 - Chromosome 3 dosage-loss informs on the unique biology underlying ultra high-risk uveal melanoma	J. L. Rose
1:30-5 p.m. Posters ⏐ Halls A, C, and F	
LBPO.IM03 - Late-Breaking Research: Immunology 3 ⏐ Section 53	
LB359 / 8 - Lung epithelial specific IL-1R promotes K-ras mutant lung cancer by inducing angiogenesis that might be medicated via myeloid tumor microenvironment	A. Krishna
PO.BCS01.11 - Integrative Computational Approaches 2 / Sequence Analysis / Systems Engineering ⏐ Section 53	
6237 / 7 - Large-scale imputation models for multi-ancestry proteome-wide association analysis	C. Wu
6253 / 23 - Single-cell RNA sequencing reveals metastatic site-specific biomarkers for predicting response to CDK4/6 inhibition in advanced HR+/HER2- breast cancer	L. Luo
PO.BCS02.01 - Integrative Cancer Science ⏐ Section 36	
6200 / 3 - Single-cell analyses unravel novel immune and tumor cell characteristics linked to the response to neoadjuvant immune checkpoint blockade in patients with gastric cancer	E. Dai
6216 / 19 - Single cell DNA sequencing of BRAF treatment resistant anaplastic thyroid cancer	A. Thennavan
PO.BCS02.02 - Detection, Imaging, and Pathology ⏐ Section 35	
6165 / 1 - Early detection of pancreatic cancer by hyperpolarized magnetic resonance	P. L. Smith
6171 / 7 - Evolution of the spatial myeloid-lymphoid engagement in glioblastoma under temozolomide treatment	S. P. Castillo
6184 / 20 - A novel approach to Barrett's esophagus risk stratification: Whole-slide image analysis for aneuploidy detection	C. Ercan
PO.CL01.10 - Predictive Biomarkers 5 ⏐ Section 43	
6391 / 3 - Spatial proteomic profiling unveils pre-existing anti-tumor immunity as a hallmark of exceptional benefit from immunotherapy in NSCLC	S. Hernandez
6392 / 4 - Activity of HER2-and TROP2- antibody drug conjugates (ADCs) in small cell lung cancer (SCLC) models with SLFN11 as a predictive biomarker	B. Zhang
6404 / 16 - GRB2 stabilizes RAD51 at reversed replication forks restricting genomic instability and associated innate immune response	Z. Ahmed
6407 / 19 - Identification of novel chemotherapy-related CHIP variations in patients with high-grade serous ovarian cancer	S. Corvigno
PO.CL06.08 - Antibodies 2 ⏐ Section 41	
6341 / 2 - Targeting myeloid epithelial tyrosine kinase (MERTK) receptor in acute myeloid leukemia using a novel antibody-drug conjugate, RGX-019-MMAE	A. Tyagi
PO.CL06.09 - Tumor Microenvironment and Cancer Immunity ⏐ Section 41	
6532 / 17 - Blockade of CD24 sensitizes pancreatic cancer to Kras inhibitors	Y. Wei
PO.CT02.02 - Phase II Clinical Trials 2 ⏐ Section 48	
CT264 / 23 - Improved clinical outcomes in patients received treatment beyond tumor progression with AdAPT-001 +/- a checkpoint inhibitor	A. P. Conley
PO.CTP02.01 - Phase II and Phase III Clinical Trials in Progress ⏐ Section 50	
CT277 / 7 - BGB-LC-201 (NCT05635708): A Phase II, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)	G. Blumenschein, Jr
CT289 / 19 - A Phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)	E. Dumbrava
CT292 / 22 - Phase II study of pembrolizumab in combination with lenvatinib in patients with triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and other tumor types and brain metastases	E. Dumbrava
PO.EN01.02 - Molecular, Preclinical, and Clinical Endocrinology 2 ⏐ Section 38	
6279 / 18 - Estrogen signaling in low-grade serous ovarian carcinoma	K. K. Wong
PO.ET01.05 - Novel Biologic Therapies and Therapeutic Targets ⏐ Section 27	

5972 / 20 - Therapeutic modulation of rock overcomes metabolic adaption to oxphos inhibition and suppresses tumor growth	N. Blazanin
5974 / 22 - Targeting VEGFR on tumor cells and activated vasculature through delivery of granzyme B	K. A. Mohamedali

PO.ET03.03 - Mechanisms of Drug Resistance 3 | Section 24

5857 / 1 - Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained	M. B. Nilsson
5864 / 8 - YAP1 defines a highly plastic, persister cell population in small cell lung cancer (SCLC) following relapse	C. Stewart

PO.ET03.07 - Drug Resistance 3: Regulation of Gene Expression | Section 23

5833 / 9 - Genomic mechanisms of RET inhibitor resistance in RET-fusion positive NSCLC	X. Liu

PO.ET08.02 - Radiation, Theranostics, Radiotheranostics, Normal Tissue, and Cellular Stress | Section 29

6031 / 13 - Fasting associated microbiota contributes to small intestinal radioprotection by modulating the epigenome	P. Barrodia

PO.IM02.04 - Inflammation in Tumor Initiation and Progression | Section 4

5326 / 6 - Selective deletion of estrogen receptor β in lung epithelium suppresses K-ras mutant lung tumorigenesis	M. J. Clowers

PO.MCB08.04 - Genomic Changes and Intratumoral Heterogeneity as Predictive Biomarkers for Clinical Outcome | Section 16

5656 / 2 - Longitudinal spatial profiling reveals chemoresistance mechanisms and characteristics of minimal residual disease in high-grade serous ovarian cancer	Y. Dai
5671 / 17 - Profiling intra-tumor heterogeneity and chromosomal instability in malignant peripheral nerve sheath tumors	Y. Cheng

PO.PR01.06 - Biomarker-Based Screening | Section 31

6077 / 3 - Chimeric RNAs are abundantly expressed in precancerous breast tissue of sporadic breast cancer patients	A. Bhardwaj
6098 / 24 - Spatial single-cell immune microenvironment analysis reveals the transition from innate to adaptive immune response during early lung adenocarcinoma carcinogenesis	B. Zhu

PO.TB06.03 - Pediatric Cancer Microenviroment, Tumor Heterogeneity, and Targeted Therapeutics | Section 9

5462 / 7 - Single-cell spatial proteomic analysis to explore the spatial heterogeneity of desmoplastic small round cell tumors	D. Truong

PO.TB11.06 - Tumor-Immune System Cross-Talk | Section 12

5547 / 3 - Non-invasive monitoring of tumor biomechanics and implications for immunotherapy in HCC	A. C. Cortes

PO.TB11.14 - Spatial Resolution of the Tumor Microenvironment | Section 10

5483 / 5 - Macrospatial ecotype heterogeneity in early-stage breast cancer identified by spatial nucleus barcoding	Z. Xiao
5486 / 8 - Spatial profiling reveals unique immune-transcriptomic features of tertiary lymphoid structures in melanoma	M. Chelvanambi

Wednesday, April 10

9 a.m.-12:30 p.m.	Posters	Halls A, C, and F

LBPO.CL03 - Late-Breaking Research: Clinical Research 3 | Section 52

LB402 / 3 - In vivo efficacy of anti-B7-H3 antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd; DS-7300): An update from the Pediatric Preclinical In Vivo Testing (PIVOT) Program	R. Gorlick

LBPO.ET04 - Late-Breaking Research: Experimental and Molecular Therapeutics 4 | Section 54

LB427 / 3 - UBA1 blockade induces homologous recombination deficiency and is synthetic lethal with PARP inhibition	N. Sahni

PO.BCS01.13 - New Software Tools for Data Analysis | Section 35

7412 / 7 - METI: Deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics	J. Jiang
7417 / 12 - SpatialCS: A tool to effectively integrate histological annotations and spatial transcriptomics analysis	Y. Chu
7424 / 19 - iStarTLS: Advanced detection and phenotyping of tertiary lymphoid structures	K. Cho

PO.CL01.22 - Prognostic Biomarkers 2 | Section 46

7662 / 23 - Convolutional neural network algorithms and hematoxylin-and-eosin-stained images predict clinical outcomes in high-grade serous ovarian cancer patients with advanced age and stage	C. Ng

PO.CL06.10 - Immune Checkpoint Inhibitor Therapy ⏐ Section 46	
7523 / 11 - An integrated analysis of radiologic and pathological responses in patients with metastatic renal cell carcinoma who presented with primary renal tumor in situ and received first-line nivolumab plus ipilimumab followed by cytoreductive nephrectomy	L. Campos Clemente
PO.CL13.03 - Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and Gene Expression ⏐ Section 43	
7547 / 4 - Enhancers as targets for improvements in immunotherapy	K. Rai
7548 / 5 - Role of bromodomain extra terminal inhibitor (BETi) in combination with radiotherapy for the treatment of NF1-associated malignant peripheral nerve sheath tumor	A. A. Gingrich
7549 / 6 - Overcoming resistance to anti-VEGF therapy via epigenetic regulation of BARD1	E. Bayraktar
PO.IM01.09 - Vaccines, Antigens, and Antigen Presentation 2 ⏐ Section 4	
6738 / 7 - Overlapping and distinct mechanisms of effective neoantigen cancer vaccines and immune checkpoint therapy	S. Keshari
PO.PS01.09 - Genetic Epidemiology 2: Family Studies, Pathway Analysis, and Functional Genetics ⏐ Section 31	
7334 / 16 - Germline mutations in cancer susceptibility genes in patients with mucosal melanoma	A. Amouzegar
PO.TB10.01 - Tumor Evolution at Single Cell Resolution ⏐ Section 11	
6933 / 11 - Decoding the archetypes and eco-hubs of triple-negative breast cancer in responses to chemotherapy	Y. Yan
6937 / 15 - High throughput single cell simultaneous DNA and RNA sequencing identified cell-of-origin of breast cancer	K. Wang
PO.TB11.04 - Chemokines and Cytokines in Cancer ⏐ Section 7	
6799 / 4 - The impact of targeting TRAF2 and NCK-interacting protein kinase on anti-tumor effect and tumor immune environment in cMYC-high small cell lung cancer	A. Tanimoto